Ardeagen Corporation Information

Ardeagen is leveraging over 28 years of biologics drug development experience of its founder, Morris Z. Rosenberg, DSc. Dr. Rosenberg has held positions at Biogen, Eli Lilly, and most recently, Seattle Genetics, where he was the EVP of Development for 11 years. During his tenure at Seattle Genetics, Dr. Rosenberg helped develop one of the world's leading antibody drug conjugate platforms and played a key role in the launch of AdcetrisTM for Hodgkin Lymphoma and ALCL. A network of consultants, CRO's, and CMO's also supports Ardeagen. Dr. Rosenberg established these relationships over the past decade while developing several antibody drug conjugate candidates at Seattle Genetics and with several other companies that Dr. Rosenberg has worked for in a consulting role.